KeyCorp (NYSE:KEY) hit a new 52-week high Thursday as it is currently trading at $11.08, above its previous 52-week high of $11.06 with seven million shares traded as of 1:50 p.m. ET. Average volume has been 10.5 million shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- KeyCorp (NYSE: KEY) hit a new 52-week high Thursday as it is currently trading at $11.08, above its previous 52-week high of $11.06 with seven million shares traded as of 1:50 p.m. ET. Average volume has been 10.5 million shares over the past 30 days. KeyCorp has a market cap of $9.87 billion and is part of the financial sector and banking industry. Shares are up 29.2% year to date as of the close of trading on Wednesday. KeyCorp. operates as the holding company for KeyBank National Association that provides various banking services in the United States. The company has a P/E ratio of 12, below the S&P 500 P/E ratio of 17.7.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates KeyCorp as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, expanding profit margins, attractive valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full KeyCorp Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..